Tag: ATH434

Browse exclusive Tags!

Alterity Therapeutics to Host Investor Webcast on Recent Clinical Progress and Efficacy Data of ATH434 in Neurodegenerative Diseases, Australia

Discover the latest clinical progress and efficacy data of ATH434 in neurodegenerative diseases with Alterity Therapeutics' CEO in an upcoming investor webcast. Register now for valuable insights!

Promising Data on ATH434 Revealed at Neuroscience Conference, Signaling Potential Breakthrough in Neurodegenerative Disease Treatment

New data on ATH434 at Neuroscience Conference reveals potential breakthrough in neurodegenerative disease treatment. Promising results for Parkinson's and MSA.

Alterity Therapeutics Receives A$4.74M Cash Refund for Research and Development, Advancing Clinical Trials for ATH434, Australia

Alterity Therapeutics receives A$4.74M cash refund for research, further advancing neurodegenerative disease treatments.

Popular

Promising Data on ATH434 Revealed at Neuroscience Conference, Signaling Potential Breakthrough in Neurodegenerative Disease Treatment

New data on ATH434 at Neuroscience Conference reveals potential breakthrough in neurodegenerative disease treatment. Promising results for Parkinson's and MSA.

Alterity Therapeutics to Host Investor Webcast on Recent Clinical Progress and Efficacy Data of ATH434 in Neurodegenerative Diseases, Australia

Discover the latest clinical progress and efficacy data of ATH434 in neurodegenerative diseases with Alterity Therapeutics' CEO in an upcoming investor webcast. Register now for valuable insights!

Subscribe

spot_imgspot_img